| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Etonogestrel (ORG3236; ORG-3236; Nexplanon; Implano; NuvaRing; Circlet) is a synthetic progestin derivative with long half-life that is an active metabolite of desogestrel and has been used in numerous hormonal contraceptive devices. It is a birth control pill that women can use as an implant under their skin under their upper arm or as a vaginal ring combined with ethinylestradiol.
| Targets |
Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
Etonogestrel reduces fertility through preventing the release of luteinizing hormone (LH), a reproductive hormone crucial to ovulation.
Etonogestrel also makes cervical mucus more viscous, which prevents spermatozoa from passing through and modifies the uterine lining to stop a fertilized egg from implanting into the endometrium. Etonogestrel, a progestin, is an oxidative substrate of CYP 3A4. Etonogestrel induces the expression of FKBP51 mRNA and protein in cultured human endometrial stromal cells (HESCs)[1]. |
| ln Vivo |
Etonogestrel (Implanon, Nexplanon, 3-Oxodesogestrel, 3-keto-Desogestrel) is a synthetic version of progesterone, a hormone that is naturally present in female sex.
|
| Cell Assay |
In basal medium (BM), which is a 1:1 v/v mixture of Dulbecco's MEM and Ham's F-12 without phenol red, thawed HESCs are grown to confluence with 100U/ml penicillin, 100μg/ml streptomycin, and 0.25μg/ml fungizone complex supplemented with 10% charcoal-stripped calf serum. Confluent HESCs are cultured in parallel in BM with 0.1% ethanol (vehicle control), 10 nM ethradiol or E2+100 nM progesterone, or 100 nM of either MPA (medroxyprogesterone acetate) or ETO (etonogestrel). The cultures are kept in a serum-free defined media (DM) that contains BM plus ITS+ (insulin, transferrin, selenium, and linoleic acid) premix, 5 μM of FeSO4, 50 μM of ZnSO4, 1 nM of CuSO4, 20 nM of Na2SeO3 trace elements, 50 μg/ml of ascorbic acid, and 50 ng/ml of recombinant epidermal growth factor. The cultures are kept in this medium for seven days after the serum is removed twice using 1X phosphate-buffered saline (PBS) to remove any remaining serum. After twice washing the cultures in 1X PBS to get rid of any remaining steroids, DM containing the appropriate vehicle control or steroids is added to the cultures for either six or twenty-four hours. Following their incubation periods, HESCs are stored at −70°C after being rinsed with ice-cold 1X PBS and prepared for total RNA and protein extraction.
|
| References |
|
| Molecular Formula |
C22H28O2
|
|---|---|
| Molecular Weight |
324.4565
|
| Exact Mass |
324.2089
|
| Elemental Analysis |
C, 81.44; H, 8.70; O, 9.86
|
| CAS # |
54048-10-1
|
| Related CAS # |
54048-10-1
|
| Appearance |
Solid powder
|
| SMILES |
CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
|
| InChi Key |
GCKFUYQCUCGESZ-BPIQYHPVSA-N
|
| InChi Code |
InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
|
| Chemical Name |
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
|
| Synonyms |
ORG 3236; ORG3236; ORG-3236; Implanon; Etonogestrel; nexplanon; 3-keto-desogestrel, 3-ketodesogestrel, 3-oxo desogestrel, 3-oxodesogestrel
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~65 mg/mL (154.1~200.3 mM)
Ethanol: 65 mg/mL (~200.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0820 mL | 15.4102 mL | 30.8204 mL | |
| 5 mM | 0.6164 mL | 3.0820 mL | 6.1641 mL | |
| 10 mM | 0.3082 mL | 1.5410 mL | 3.0820 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05237141 | Recruiting | Drug: Etonogestrel implant | Contraception | University of Colorado, Denver | April 1, 2022 | Phase 4 |
| NCT05760144 | Recruiting | Drug: DMPA Drug: Etonogestrel implant |
Contraception | Oregon Health and Science University |
July 1, 2023 | Early Phase 1 |
| NCT04047875 | Recruiting | Drug: Placebo Drug: Norethisterone 10mg/day |
Breakthrough Bleeding | University of Sao Paulo | September 15, 2020 | Phase 4 |
| NCT04423055 | Recruiting | Drug: Etonogestrel contraceptive implant |
Contraception | University of California, Davis | August 13, 2020 | Phase 4 |
| NCT05791799 | Not yet recruiting | Drug: Etonogestrel | Systemic Lupus Erythematosus | Sixth Affiliated Hospital, Sun Yat-sen University |
April 1, 2023 | Phase 2 Phase 3 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
